Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in multiple sclerosis: ten years' experience.

Ayman Tourbah1, Olivier Lyon-Caen

  • 1Service de Neurologie et Faculté de Médecine, CHU de Reims, Reims, France. ayman.tourbah@psl.aphp.fr

Biochimie
|June 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxocara seropositivity in sensory-predominant cervical myelitis from an endemic region: A six-case series and systematic review.

Multiple sclerosis and related disorders·2026
Same author

Venous sinus stenting under conscious sedation.

Journal of neurointerventional surgery·2024
Same author

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.

JAMA network open·2021
Same author

MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis.

Multiple sclerosis and related disorders·2021
Same author

Social cognition and executive functioning in multiple sclerosis: A cluster-analytic approach.

Journal of neuropsychology·2021
Same author

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.

Neurology(R) neuroimmunology & neuroinflammation·2021

Interferon beta (IFN beta) treatments for multiple sclerosis (MS) reduce relapses but raise questions about comparisons, administration, and long-term disability effects.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Interferons (IFNs) have been explored for multiple sclerosis (MS) treatment.
  • Early studies indicated efficacy of interferon beta (IFN beta) in reducing exacerbations for relapsing-remitting MS.
  • Three IFN beta preparations are approved: IFN beta-1b, intramuscular IFN beta-1a, and subcutaneous IFN beta-1a.

Purpose of the Study:

  • To review the current understanding and remaining questions regarding interferon beta therapies in multiple sclerosis.
  • To address controversies surrounding different preparations, administration routes, and dosages.
  • To evaluate the long-term impact on disability and the role of neutralizing antibodies.

Main Methods:

  • Review of existing clinical studies and approved therapeutic guidelines for IFN beta in MS.

Related Experiment Videos

  • Analysis of data concerning relapse rates, administration routes, and dosage variations.
  • Examination of literature on neutralizing antibodies and long-term disability outcomes.

    • Main Results:

    • IFN beta therapies are established for reducing relapse rates in relapsing-remitting MS.
    • Significant challenges exist in comparing different IFN beta preparations and administration routes.
    • The long-term effects on disability progression remain insufficiently demonstrated.

    Conclusions:

    • While IFN beta treatments are beneficial for reducing MS relapses, critical questions persist.
    • Further research is needed to clarify optimal use, compare preparations, and understand long-term disability impact.
    • The role of neutralizing antibodies requires further elucidation for personalized treatment strategies.